About this trial
This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.
Eligibility criteria
Qualifiers
Histologically proven diagnosis of adenocarcinoma or squamous cell carcinoma of the thoracic esophagus or gastroesophageal junction (Siewert I-II)
History/physical examination
Whole-body fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) with or without contrast (preferred) or chest/abdominal (include pelvic if clinically indicated) CT with contrast
For patients who DID NOT receive induction chemotherapy, scan must occur within 30 days prior to Step 1 registration
Disqualifiers
Cervical esophageal cancers arisen from 15-18 cm from the incisors
Patients with T4b disease according to the AJCC 8th edition
Definitive clinical or radiologic evidence of metastatic disease
Any active malignancy within 2 years of study registration that may alter the course of esophageal cancer treatment
Trial design
Treatments tested in this trial
- Biospecimen Collection
- Capecitabine
- Carboplatin
- Computed Tomography
- Docetaxel
- Esophagectomy
- Fluorouracil
- Intensity-Modulated Radiation Therapy
- Leucovorin Calcium
- Oxaliplatin
- Paclitaxel
- Positron Emission Tomography
- Proton Beam Radiation Therapy
- Quality-of-Life Assessment
- Questionnaire Administration
Treatment groups
Sponsors and collaborators
NRG Oncology
Lead sponsor
National Cancer Institute (NCI)
Collaborator